Search
emtricitabine (Emtriva, FTC)
Tradename: Emtriva
Indications: HIV, chronic hepatitis B [3]
Dosage: 200 mg PO QD
Dosage adjustment in renal failure:
- dosage reduction if creatinine clearance < 50 mL/min
Pharmacokinetics:
1) hepatic oxidation & glucuronidation
2) cyt P450 system not involved
3) clearance 86% renal, 14% fecal
4) 2/1life 10 hours
Adverse effects:
1) well tolerated
2) hyperpigmentation on palms & soles (Blacks) 2%
3) diarrhea, headache, nausea, rash 1%
Drug interactions: unlikely
Mechanism of action:
- inhibits viral reverse transcriptase
- has activity against hepatitis B virus [3]
Interactions
drug interactions
drug adverse effects of antiretroviral agents
General
nucleoside reverse transcriptase inhibitor (NRTI)
Properties
Database Correlations
PUBCHEM cid=60877
References
- Prescriber's Letter 10(8):45 2003
- Department of Veterans Affairs, VA National Formulary
- Lim SG et al,
A double-blind placebo-controlled study of emtricitrabine in
chronic hepatitis B
Arch Intern Med 2006; 166:49
PMID: 16401810
Component-of
bictegravir/emtricitabine/tenofovir alafenamide (Biktarvy, Symtuza)
cobicistat/darunavir/emtricitabine/tenofovir
cobicistat/elvitegravir/emtricitabine/tenofovir (Quad, Stribild, Genvoya)
efavirenz/emtricitabine/tenofovir (Atripla)
emtricitabine/rilpivirine/tenofovir DF (FTC/RPV/TDF, TAF/FTC/RPV, Complera, Odefsey)
emtricitabine/tenofovir (Truvada, TDF/FTC, Descovy)